Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 36

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
   975,786   -   980,287                  OTHER INCOME                Dividend income   -   59,653   -   59,653 Interest income  80,161   33,583   -   113,744 Fair value gain on investments in equity securities  -   243,083   -   243,083 Gain on disposal of investments in equity securities  -   35,098   -   35,098 Reversal of expected credit losses  -   842,401   -   842,401 Others  18,669   84,831   -   103,500 TOTAL OTHER INCOME  98,830   1,298,649   -   1,397,479                  OPERATING EXPENSES                Sales and marketing  (78,741)  (1,419,201)  (37,879)  (1,535,821)Research and development  (30,115)  -   -   (30,115)General and administrative  (366,906)  (427,829)  (872,301)  (1,667,036)Fair value loss on investments in equity securities  -   (179,433)  -   (179,433)Provision for expected credit losses   -   (122,843)  -   (122,843)OPERATING EXPENSES  (475,762)  (2,149,306)  (910,180)  (3,535,248)                 (LOSS)/PROFIT FROM OPERATIONS  (372,431)  125,129   (910,180)  (1,157,482)                 FINANCE COSTS  (8,360)  (6,848)  (126)  (15,334)                 (LOSS)/PROFIT BEFORE TAX  (380,791)  118,281   (910,306)  (1,172,816)                 Tax expense  -   (77,207)  -   (77,207